Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive,Disease Week Meeting

Reports 'Picomolar' Potency and Slow Dissociation from HCV Protease

WASHINGTON, May 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- InterMune, Inc. (Nasdaq: ITMN) today presented new preclinical data on the company's Hepatitis C virus (HCV) NS3/4A protease inhibitor, ITMN-191, during a scientific session of the Digestive Disease Week (DDW) meeting being held May 19-24 in Washington, D.C. The reported study (DDW abstract #M1816) examined ITMN-191 potency and binding kinetics in biochemical assays.

The new InterMune study represents an in-depth characterization of the mechanism of inhibition of the HCV NS3/4A serine protease by ITMN-191. Full characterization of the inhibition mechanism indicated that ITMN-191's true biochemical potency of 36 picomolar (pM) was approximately ten-fold better than previously inferred (~ 250 pM reported at DDW 2006). The presented data also suggest that ITMN-191 binds to the NS3/4A protease target in a two-step binding mechanism in which ITMN-191 initially associates with NS3/4A in a collision complex that isomerizes to a long-lived but non-covalent drug-target complex. The half life of the complex between ITMN-191 and NS3/4A was estimated to be five hours or more, and inhibition of protease activity of NS3/4A was stable over this same time period. Slow dissociation of ITMN-191 from the NS3/4A protease may have a relevant in vivo consequence, as a two-hour exposure of ITMN-191 to tissue culture cells that harbor an HCV replicon resulted in an antiviral effect equal to that delivered by continuous exposure of ITMN-191.

Lawrence M. Blatt, Ph.D., Chief Scientific Officer of InterMune, said, "This preclinical study of ITMN-191 provides a better understanding of its attractive potency and binding characteristics. While ITMN-191 is a non-covalent, reversible inhibitor of the protease, the onset of inhibition and slow dissociation compare favorably with those
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
(Date:6/30/2015)... ... June 30, 2015 , ... The American Psychiatric Nurses ... Disney’s Coronado Springs Resort in Lake Buena Vista, Florida, and will offer more ... event for psychiatric-mental health nursing draws more than 1,500 health care professionals from ...
(Date:6/30/2015)... ... 30, 2015 , ... Medflow, the leader in the ophthalmic ... records system from the company exclusively dedicated to helping eye care professionals for ... state-of-the-art solution combining modern cloud technology with Medflow’s proven expertise in the eye ...
(Date:6/30/2015)... ... 2015 , ... Scott Purdy, the spokesperson for Dephinitive Systems LLC, announces today ... that the XO stands for eXtra Operability (XO) which was chosen to reflect the ... Revenue Cycle. , Provider XO, based in Cleveland OH, is part of the ...
(Date:6/29/2015)... ... June 30, 2015 , ... ... Richards as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
(Date:6/29/2015)... ... 2015 , ... Aespala Medspa and Plastic Surgery is proud to introduce the ... , Dr. Dreyfuss received his medical degree from Emory University in Atlanta before completing ... Surgery Fellowship at the University of Chicago. He has taught and practiced medicine in ...
Breaking Medicine News(10 mins):Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:Dephinitive Systems Is Getting a New Name 2Health News:National Association of Professional Women Inducts Melanie Richards, DMD, of Powdersville Pediatric Dentistry, Into its VIP Woman of the Year Circle 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 3
... , MONDAY, May 16 (HealthDay News) -- When general doctors ... lesion, it,s more often another lesion that turns out to ... non-dermatologists might benefit from increased education on skin cancer detection, ... see the very high number of incidentally detected skin cancers," ...
... help prevent a serious complication associated with a contrast agent ... in the July issue of Radiology . ... (GBCA) has been linked to the development of nephrogenic systemic ... kidney disease. But since 2008, restrictive GBCA administration guidelines implemented ...
... new test for prostate cancer that measures levels of prostate ... in the blood of men with the disease was more ... today, according to a study by researchers at UCLA,s Jonsson ... also reduced the rate of false-positives, tests that indicate the ...
... 16 (HealthDay News) -- Asthma patients who delay seeking ... worse outcomes, including hospitalization. That,s the finding of ... New York City emergency departments. They were asked about ... at self-management before they decided to go to the ...
... bioengineering students have modified a child-size training mannequin to ... patients can be spared further stress and pain. ... Intended for Training, as their senior design project at ... who have long recognized the need for students to ...
... is the fourth-most-common cancer in men and one of ... death. After initial diagnosis and surgery, patients must return ... time-consuming and uncomfortable bladder scan. Tumors recur in more ... Washington are proposing a more automated approach that could ...
Cached Medicine News:Health News:GPs Lack Accuracy in Spotting Skin Cancers: Study 2Health News:GPs Lack Accuracy in Spotting Skin Cancers: Study 3Health News:Contrast agent guidelines help prevent debilitating disorder 2Health News:New prostate cancer test more specific, sensitive than PSA test 2Health News:New prostate cancer test more specific, sensitive than PSA test 3Health News:Don't Delay Emergency Care When Asthma Flare-Ups Strike 2Health News:Child-size mannequin: Hands-on training spares real patients 2Health News:Child-size mannequin: Hands-on training spares real patients 3Health News:Digital imaging software to create a 'Google Earth' view of the bladder 2Health News:Digital imaging software to create a 'Google Earth' view of the bladder 3
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... IQmark family elevates your ECG and Spirometry capabilities ... and efficient patient care. The IQmark Diagnostic PDA ... clinics and medical centers as well as for ... conjunction with the IQmark Digital ECG PDA and ...
Medicine Products: